Details of the Drug

General Information of Drug (ID: DM1F42Z)

Drug Name
Oxatomide
Synonyms
Celtect; Oxatimide; Oxatomida; Oxatomidum; Oxetal; Tinset; CBMicro_024634; KW 4354; O 9387; R 35443; R35443; Celtect (TN); KW-4354; McN-JR 35443; Oxatomida [INN-Spanish]; Oxatomide (tinset); Oxatomidum [INN-Latin]; R 35,443; R-35443; Oxatomide (JAN/USAN/INN); Oxatomide [USAN:BAN:INN:JAN]; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
Indication
Disease Entry ICD 11 Status REF
Hay fever CA08.00 Approved [1]
Therapeutic Class
Antiallergic Agents
ATC Code
R06AE06: Oxatomide
R06AE: Piperazine derivatives
R06A: ANTIHISTAMINES FOR SYSTEMIC USE
R06: ANTIHISTAMINES FOR SYSTEMIC USE
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 426.6
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination
0% of drug is excreted from urine in the unchanged form [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.9321 micromolar/kg/day [3]
Water Solubility
The ability of drug to dissolve in water is measured as 0.043 mg/mL [2]
Chemical Identifiers
Formula
C27H30N4O
IUPAC Name
3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
Canonical SMILES
C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5
InChI
InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
InChIKey
BAINIUMDFURPJM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4615
ChEBI ID
CHEBI:31943
CAS Number
60607-34-3
UNII
J31IL9Z2EE
DrugBank ID
DB12877
TTD ID
D0AJ5L
INTEDE ID
DR1213

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hay fever
ICD Disease Classification CA08.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
2 BDDCS applied to over 900 drugs
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.